Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | PPARD | Q03181 | 7/20 | 0.55 |
| ▸ | PPARA | Q07869 | 7/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | FABP4 | P15090 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534190 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4528754 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL931159 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4530530 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL6887374 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4525726 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4520218 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4518788 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4529944 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4523441 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688761-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Tonix Pharma Limited (IE) | 2026-02-11 | — | — | EP | claimed |
| CN-119680635-A | Ionic liquid catalyst for producing renewable fuel from waste grease and preparation method and application thereof | 中国科学院青岛生物能源与过程研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-118221674-B | Pyrrolo [3,2-b ] pyridine Top/HDAC double-target inhibitor, preparation method, pharmaceutical composition and application thereof | 南京市鸿舜医药科技有限公司 | 2025-01-28 | — | — | CN | claimed |
| WO-2024206520-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2024-10-03 | — | — | WO | claimed |
| CN-118652218-A | Metconazole hapten, antigen, monoclonal antibody and preparation method and application thereof | 北京普赞生物技术有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118440090-A | Fluorescent probe of targeted lysosome and preparation method and application thereof | 南京工业大学 | 2024-08-06 | — | — | CN | claimed |
| CN-118221674-A | Pyrrolo [3,2-b ] pyridine Top/HDAC double-target inhibitor, preparation method, pharmaceutical composition and application thereof | 南京市鸿舜医药科技有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-20240116961-A1 | TRIPHENYPHOSPHINE MODIFIED SERTRALINE DERIVATIVE AND METHODS THEREOF | XIAMEN UNIVERSITY (CN) | 2024-04-11 | — | — | US | claimed |
| CN-117751938-A | Nano container loaded with anti-fouling agent and anti-fouling paint composition | 浙江鱼童新材料股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117417322-A | Tiletamide artificial hapten and artificial antigen as well as preparation methods and application thereof | 杭州同舟生物技术有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-110548398-B | Crosslinking type zwitterion group modified forward osmosis membrane and preparation method thereof | 宁波蓝盾新材料科技有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-113040145-A | Hypecox ulmoides sex attractant and preparation method thereof | 虫捕头(苏州)生物科技有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-110713533-B | 25-hydroxy vitamin D3Antigen and method for producing the same | 杭州隆基生物技术有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-110841494-A | Amphoteric composite forward osmosis membrane and preparation method and application thereof | 吾净科技(深圳)有限公司 | 2020-02-28 | — | — | CN | claimed |
| CN-110713533-A | 25-hydroxy vitamin D3Antigen and method for producing the same | 杭州隆基生物技术有限公司 | 2020-01-21 | — | — | CN | claimed |
| CN-110548398-A | crosslinking type zwitterion group modified forward osmosis membrane and preparation method thereof | NINGBO LANDUN NEW MATERIAL TECH CO LTD | 2019-12-10 | — | — | CN | claimed |
| EP-0818562-B1 | Composition for treating copper and copper alloy surfaces and method for the surface treatment | MEC CO LTD (JP) | 2000-03-22 | — | — | EP | claimed |
| EP-0818562-A1 | Composition for treating copper and copper alloy surfaces and method for the surface treatment | MEC CO., Ltd. (JP) | 1998-01-14 | — | — | EP | claimed |
| US-5496590-A | Composition for treating copper and copper alloy surfaces and method for the surface treatment | MEC CO., LTD. (JP) | 1996-03-05 | — | — | US | claimed |
| EP-0643154-A2 | Composition for treating copper and copper alloy surfaces and method for the surface treatment | MEC CO., Ltd. (JP) | 1995-03-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116961-A1 | TRIPHENYPHOSPHINE MODIFIED SERTRALINE DERIVATIVE AND METHODS THEREOF | PINK1, TPH1, HTR5A | TSHR 1175/4885LMNA 1713/4885NFKB1 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.